Letters to the Editor
Author's reply
I am grateful to Dr van Dalen for his helpful comments which are, in part, explained by the lengthy gestation of the original review. This review was aimed at clinical biochemists who are not expert in the application of tumour markers but who find themselves confronted with a vast, confusing amount of literature and an expanding range of products. The emphasis within the review was one of caution.
The criteria of response have often been illdefined or omitted from articles on tumour markers, and we sought to stress their importance by quoting those in use in one of our laboratories at the time of writing. I support the recent move towards unified criteria that can be understood internationally, and trust that this will reduce some of the current confusion.
The classification of any one tumour marker as being 'established' is by its very nature subjective. By omitting CA 125, NSE and CA 15-3 from the review, we did not imply that these markers do not have a useful role in specific clinical situations, but rather that they had not gained widespread use in clinical biochemistry laboratories in the UK. Unlike PSA, which is now widely used, these other markers are performed largely by laboratories working in close association with specialist clinical units where there is overlap between clinical trial and routine management. I am prepared to accept that CA 125 has become 'more established' in the UK during the past 2 years and that NSE and CA 15-3 are moving in that direction.
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